Capital Rx and 3 Axis Advisors Study Finds Potential for Billions in Prescription Drug Savings With Transparent Pricing Practices
Mandatory NADAC responses by pharmacies for 1,600 unique oral solid products could create additional savings of $1.5 billion over 10 years
Comparing generic drug costs with NADAC and Alabama actual acquisition cost, study finds $937 million in potential annual savings across Medicaid
Implementing and improving transparency in pricing practices can restore public...
Capital Rx and 3 Axis Advisors Study Finds Potential for Billions in Prescription Drug Savings With Transparent Pricing Practices
Mandatory NADAC responses by pharmacies for 1,600 unique oral solid products could create additional savings of $1.5 billion over 10 years
Comparing generic drug costs with NADAC and Alabama actual acquisition cost, study finds $937 million in potential annual savings across Medicaid
Implementing and improving transparency in pricing practices can restore public trust in U.S. drug pricing system, results suggest
CMS proposes delaying drugmaker rule days after PhRMA suesThe lawsuit also casts blame on health plans and pharmacy benefit managers that allegedly "siphon the benefits" meant for consumers.
Today's guests:
Antonio Ciaccia
3 Axis Advisors www.3axisadvisors.com
A. J. Loiacono
CEO at Capital Rx
https://www.healthcarefinancenews.com/news/cms-proposes-delaying-drugmaker-rule-days-after-phrma-sues
This episode is sponsored by the Ultiguard Safe Pack. UltiGuard Safe Pack is the only pen needle product that comes with an all-in-one sharps container. Learn more about why UltiGuard Safe Pack is the best choice for your patients and your pharmacy.,
Learn more about the UltiGuard Safe Pack:
https://www.ulticare.com/ultiguard-safe-pack/podcast
See omnystudio.com/listener for privacy information.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View more